|
|
Article: Roche adopts Fluofarmas high-content screening platform.
- Article from:
- Biotech Week
- Article date:
- November 18, 2009
CopyrightCOPYRIGHT 2009 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Fluofarma, a leading company in High Content Screening (HCS) technologies, which offers services and counseling to the Pharmaceutical industry, announced that it entered into a multi-year agreement with Roche.
The collaboration will be focused on the development and miniaturization of innovative cell based assays using high throughput flow cytometry and on the development of computational models which can be used to improve the predictability of hepatotoxicity and the safety profiling of compounds in liver cells (see also Biotech Business).
Under the terms of the research collaboration and license agreement, Roche and Fluofarma will work together to ...